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Van der Woude et al.1 have demonstrated that
compared to placebo, the Borg score returned
significantly quicker to baseline value after inhala-
tion of formoterol, salmeterol and salbutamol.
These results were observed following methacho-
line challenge during which the forced expiratory
volume in 1 s (FEV1) was required to fall by at least
30%. While expected, these findings may only be of
relevance to patients with mild asthma who are
steroid naı¨ve or who use regular inhaled corticos-
teroids alone.
In everyday clinical practice, many asthmatics with
moderate-to-severe disease—especially those with
impaired FEV1—are maintained on combined inhaled
corticosteroid plus long-acting b2-agonist prepara-
tions. Despite the theoretical compliance benefit, it
is important to note that regular use of the long-
acting b2-agonist moiety is known to blunt the effects
of salbutamol.2 In other words, patients using regular
long-acting b2-agonists experience a more prolonged
recovery despite acute salbutamol administration.
Several studies have demonstrated that prior
administration of a leukotriene CysLT1-receptor
antagonist significantly shortens the time taken to
recover following bronchial challenge,3–5 with the
implication that cysteinyl leukotrienes are integral
pro-inflammatory mediators in maintaining the
bronchoconstrictor response. Indeed, the ‘real-life’
implication of this was observed in a study by
Camargo et al.6 In this double-blind, parallel group
controlled trial, 210 patients with acute asthma
were randomised to receive either montelukast or
placebo along with conventional therapy. Patients
given active drug had a significantly more rapid
improvement in FEV1 over a 2-h period and received
less inhaled b2-agonist compared to placebo.
In conclusion, it is important to bear in mind that
the findings of van der Woude et al. should only be
applied to patients who do not use regular long-
acting b2-agonist. Moreover, use of a leukotriene
CysLT1-receptor antagonist such as montelukast isee front matter & 2004 Elsevier Ltd. All rights reserv
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nal article 10.1016/j.rmed.2004.03.001an effective means of shortening the recovery time
following an acute episode of bronchoconstriction,
irrespective of prior use of long-acting b2-agonist.
Whether leukotriene CysLT1-receptor antagonists
should be used along with standard therapy in
emergency departments to quicken the time taken
to recover remains to be seen.
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